2025-10-22

Q3 2025 Results

Financial data not available in provided excerpt

2025-07-24

Q2 2025 Results

Data unavailable - XBRL metadata only

2025-04-23

Q1 2025 Results

Financial data not available in provided content

2024-10-23

Q3 2024 Results

Financial data not available in provided content

2024-07-25

Q2 2024 Results

2024-05-01

Q1 2024 Results

Financial figures not clearly extractable from provided XBRL structure

2025-02-13

FY2024 Results

📌 Kenvue consumer products business IPO and spinoff completed in 2023, focusing JNJ on pharma and medtech segments

2024-02-16

FY2023 2023 Results

📌 Kenvue IPO completed on May 8, 2023 - J&J spun off consumer products division

2025-10-14

Q3 Earnings + Orthopaedics Spinoff

Q3 2025 results + separating Orthopaedics business

2025-09-09

Board Director Elected

John Morikis elected to Board, former Sherwin-Williams CEO

2025-07-16

Q2 2025 Earnings

Q2 ended June 29, 2025 results

2025-06-10

Director Elected

Daniel Pinto (JPMorgan President) joins board July 1

2025-04-30

Director Retirement & Annual Meeting

D. Adamczyk retiring May 31, all 11 directors elected

2025-04-15

Q1 Earnings & Dividend Hike

Q1 2025 results + dividend increased 4.8% to $1.30/share (63rd consecutive year)

2025-04-03

Bankruptcy Plan Denied

$7B reserve reversal from Red River Talc bankruptcy denial

2025-02-26

Euro Bond Offering

€4B notes across 5 tranches, 2.7%-3.7% coupons, 2029-2055 maturities

2025-02-20

Debt Offering

$5B notes issued, rates 4.5%-5.0%

2025-01-22

Q4 2024 Earnings

Q4 and full year 2024 results announced

2024-10-15

Q3 Earnings

Q3 2024 results for period ended Sept 29

2024-09-20

Talc Litigation Bankruptcy Settlement

$8B settlement via subsidiary Chapter 11 filing

2024-09-10

Director Retirement

D.S. Davis retired as Director, Audit Committee Chair transition to D. Adamczyk

2024-08-26

CHRO Retirement

Peter M. Fasolo retiring October 1, 2024

2024-07-17

Q2 Earnings

Q2 2024 results for period ended June 30, 2024

2024-05-20

Multi-Tranche Debt Offering

$6B total: $4B USD notes (4.8-5.25%) + €2.5B EUR notes (3.2-3.55%)

2024-05-17

Completed Kenvue Divestiture

Exchanged remaining 182M Kenvue shares for $3.6B commercial paper

2024-05-01

Q1 Earnings + $6.5B Talc Settlement

EPS revised down from $2.20 to $1.34 due to $2.7B incremental talc charge

2024-04-29

Annual Shareholder Meeting & Bylaws Amendment

All 13 directors elected, bylaws updated for special meetings and proxy rules

2024-04-16

Q1 Earnings & Dividend Increase

Q1 2024 results released, dividend raised 4.2% to $1.24/share (62nd consecutive year)